Therapeutic Modifications without Discontinuation of Atezolizumab Plus Bevacizumab Therapy Are Associated with Favorable Overall Survival and Time to Progression in Patients with Unresectable Hepatocellular Carcinoma

SIMPLE SUMMARY: We aimed to evaluate the impact of therapeutic modifications of atezolizumab (Atezo) plus bevacizumab (Bev) therapy (Atezo/Bev) in the case of intolerable adverse events on the prognosis of patients with unresectable hepatocellular carcinoma. Therapeutic modifications included the in...

Descripción completa

Detalles Bibliográficos
Autores principales: Tokunaga, Takayuki, Tateyama, Masakuni, Kondo, Yasuteru, Miuma, Satoshi, Miyase, Shiho, Tanaka, Kentaro, Narahara, Satoshi, Inada, Hiroki, Kurano, Sotaro, Yoshimaru, Yoko, Nagaoka, Katsuya, Watanabe, Takehisa, Setoyama, Hiroko, Fukubayashi, Kotaro, Tanaka, Motohiko, Tanaka, Yasuhito
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10001232/
https://www.ncbi.nlm.nih.gov/pubmed/36900359
http://dx.doi.org/10.3390/cancers15051568

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10001232/
https://www.ncbi.nlm.nih.gov/pubmed/36900359
http://dx.doi.org/10.3390/cancers15051568

Ejemplares similares